Author: Zacks Small Cap Research

1234514930 / 1489 POSTS
By Lisa Thompson OTC:LGIQ READ THE FULL LGIQ RESEARCH REPORT Logiq (OTC:LGIQ) preannounced Q4 revenues of $12.3 million, coming in well above our November estimate of $8.8 million. Although company did not give the breakdown between AppLogiq and Data ...
By Beth Senko, CFA OTC:MITI READ THE FULL MITI RESEARCH REPORT Healthcare delivery in the US was undergoing a revolution well before COVID-19, driven by an influx of newly-insured patients from the Affordable Care Act, a shortage of primary care prov ...
By David Bautz, PhD NASDAQ:EDSA READ THE FULL EDSA RESEARCH REPORT Business Update Data Readouts for EB05 and EB01 Clinical Trials Expected in 2022 Edesa Biotech, Inc. (NASDAQ:EDSA) is currently conducting two clinical trials for its lead assets EB05 ...
By John Vandermosten, CFA NASDAQ:TENX READ THE FULL TENX RESEARCH REPORT Clinical Program Update On January 4, 2022, Tenax Therapeutics, Inc. (NASDAQ:TENX) provided an update on TNX-102 (subcutaneous levosimendan), TNX-103 (oral levosimendan) and TNX ...
By John Vandermosten, CFA NASDAQ:BCTX READ THE FULL BCTX RESEARCH REPORT We are initiating coverage of BriaCell Therapeutics Corp. (NASDAQ:BCTX). This value is based on our estimates for a successful development and commercialization of Bria-IMT for ...
By Lisa Thompson NASDAQ:OIIM READ THE FULL OIIM RESEARCH REPORT O2Micro (NASDAQ:OIIM) is now saying Q4 revenues should now be approximately $24 million in Q4 primarily due to short term supply chain issues with one of the wafer suppliers supporting i ...
By Lisa Thompson NYSE:DSS READ THE FULL DSS RESEARCH REPORT On December 23, 2021, a subsidiary of DSS (NYSE:DSS) entered into an agreement with Sharing Services Global Corporation providing for an investment of up to $3 million in exchange for 50 mil ...
By John Vandermosten, CFA NASDAQ:GBS READ THE FULL GBS RESEARCH REPORT The number of diagnostic tests used to evaluate biological material has exploded over the last decades. These tests help identify disease, determine treatment and show whether or ...
By John Vandermosten, CFA CNSX:ORTH.CN | OTC:ORTIF READ THE FULL ORTH.CN RESEARCH REPORT Clinical Hold Letter Lifted Following the April 2021 Investigational New Drug (IND) submission for Ortho-R, Ortho Regenerative Technologies Inc. (CNSX:ORTH.CN) ( ...
By M. Marin OTC:XPHYF Focused on next-generation diagnostics, drug delivery, and drug development opportunities … XPhyto Therapeutics (OTC:XPHYF), a bioscience accelerator focused on opportunities in the areas of next-generation diagnostics, drug del ...
1234514930 / 1489 POSTS